AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL

Shots: AstraZeneca reported long-term follow-up from the positive P-ll ACE-LY-004 study involves assessing Calquence (acalabrutinib) in adult patients with r/r MCL Result: @median follow up (38.1mos.) 44% of patients either remained on treatment or continued to be followed for survival; median DOR (28.6 mos.); estimated DOR rate @36 mos. (41.9%); m-PFS (22 mos.); estimated PFS …

AstraZeneca Reports Long-Term Efficacy and Tolerability of Calquence (acalabrutinib) in P-ll ACE-LY-004 Study for MCL Read More »